stockrowZoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024.
- Revenue
- −0.24%
- EPS
- +2.48%
- Free cash flow
- +17.4%
- Total debt
- +37.5%
Quarter to June 2026, against a year earlier
Follow ZTS
Alert me
Zoetis Inc. (ZTS) Return on invested capital
Zoetis Inc.'s return on invested capital over the twelve months to 30 June 2026 was 19.6%, down 1.3 percentage points from fiscal 2025 (20.9%). Over the past ten years it has ranged from 7.09% (fiscal 2015) to 20.9% (fiscal 2024); the current reading is higher than 91% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 20.9% | (0.07) |
| FY2024 | 20.9% | 1.66 |
| FY2023 | 19.3% | 0.26 |
| FY2022 | 19.0% | (1.20) |
| FY2021 | 20.2% | 3.29 |
| FY2020 | 16.9% | 1.34 |
| FY2019 | 15.6% | 0.36 |
| FY2018 | 15.2% | (3.19) |
| FY2017 | 18.4% | 3.77 |
| FY2016 | 14.7% | 7.56 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| UTHR United Therapeutics Corporation compare | 30.1% |
| ZTS Zoetis Inc. | 19.6% |
| NBIX Neurocrine Biosciences, Inc. compare | 17.7% |
| RDY Dr. Reddy's Laboratories Ltd compare | 4.77% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 4.09% |
| ELAN Elanco Animal Health Incorporated compare | 0.51% |
| TAK Takeda Pharmaceutical Co. compare | 0.00% |
| HLN Haleon PLC Sponsored ADR compare | 0.00% |
| VTRS Viatris Inc. compare | −0.02% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement